| Execution period | 90 days |
|---|
BSE filing, NSE: TIMETECHNO. Summary written from the filing by ALFA Finder's alert engine.
Time Technoplast Ltd: key numbers
- Share price
- ₹162.75
- Market cap
- ₹8,034 Cr
- Revenue (annual)
- ₹6,105 Cr
- Net profit (annual)
- ₹468.7 Cr
- P/E (TTM)
- 16.4×Sector 52.2×
- Promoter holding
- 47.47%-0.09% QoQ
- FII holding
- 9.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Time Technoplast Ltd
All →Time Technoplast Board Meeting Date
Time Technoplast has scheduled its Board meeting for 05 Nov 2026. The proposed agenda covers Q1/H1 results and a postal ballot to re-appoint the Managing Director.
Time Technoplast Debt & Borrowing: ₹10 Cr
Time Technoplast fully redeemed its commercial paper, worth ₹10.00 Crore, at maturity on October 23, 2026. The filing covers Series I, with 200 instruments of ₹5 lakh face value each.
- Value
- ₹10.00 Cr
Time Technoplast Debt & Borrowing: ₹25 Cr
Time Technoplast Ltd has completed the full redemption of its Commercial Paper (ISIN: INE508G14IU5) worth ₹25 Crore upon maturity on October 19, 2026.
- Value
- ₹25.00 Cr
Time Technoplast Debt & Borrowing
Time Technoplast Limited has successfully repaid the maturity amount for its commercial paper. The payment obligation was fulfilled on October 05, 2026, for ISIN INE508G14IN0.
Time Technoplast Debt & Borrowing: ₹35 Cr
Time Technoplast Limited has redeemed Commercial Papers worth ₹35.00 Crore upon maturity. The full redemption was completed on October 5, 2026, leaving zero outstanding amount.
- Value
- ₹35.00 Cr
Time Technoplast Other Announcement
Time Technoplast Ltd submitted its quarterly certificate for the period ended September 30, 2026. The document confirms the utilization of Commercial Paper proceeds for specified purposes.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.